LONDON--(Marketwire - October 15, 2007) - Antisoma plc (LSE: ASM; US OTC: ATSMY) today announces that it has received further data from its 74- patient randomised phase II trial of ASA404 in hormone-refractory prostate cancer. This trial compares patients receiving 1200 mg/m2 ASA404 plus docetaxel with patients receiving docetaxel alone:
